Drug company agrees to settle Paxil birth defect cases
The manufacturer of Paxil, GlaxoSmithKline, has agreed to pay more than $1 billion to resolve more than 800 cases alleging its Paxil antidepressant caused birth defects in some users’ children. The agreement still leaves upwards of 100 Paxil birth defect cases unresolved and pending. Glaxo recently admitted that it has set aside a total of $2.4 billion to cover damages and expenses in cases involving Paxil and also Avandia, a diabetes medicine. In addition to claims that Paxil caused birth defects in user's children, there are also claims that Paxil caused addiction problems and suicides or attempted suicides.